MDGL Quote, Financials, Valuation and Earnings

Insmed, Inc. has a net margin of -18.24% compared to Madrigal Pharmaceuticals, Inc.'s net margin of -124.5%. Madrigal Pharmaceuticals, Inc.'s return on equity of -42.53% beat Insmed, Inc.'s return on equity of -192.35%.

Madrigal Pharmaceuticals, Inc. has a consensus price target of $668.57, signalling upside risk potential of 22.25%. On the other hand Insmed, Inc. has an analysts' consensus of $214.32 which suggests that it could grow by 31.94%. Given that Insmed, Inc. has higher upside potential than Madrigal Pharmaceuticals, Inc., analysts believe Insmed, Inc. is more attractive than Madrigal Pharmaceuticals, Inc..

Madrigal Pharmaceuticals, Inc. has a beta of -0.995, which suggesting that the stock is 199.535% less volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.100, suggesting its more volatile than the S&P 500 by 10.036%.

Madrigal Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Madrigal Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.

Madrigal Pharmaceuticals, Inc. quarterly revenues are $321.1M, which are larger than Insmed, Inc. quarterly revenues of $263.8M. Madrigal Pharmaceuticals, Inc.'s net income of -$58.6M is higher than Insmed, Inc.'s net income of -$328.5M. Notably, Madrigal Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals, Inc. is 13.20x versus 53.27x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -18.24% compared to Madrigal Pharmaceuticals, Inc.'s net margin of 34.4%. Madrigal Pharmaceuticals, Inc.'s return on equity of -42.53% beat Eli Lilly & Co.'s return on equity of 104.39%.

Madrigal Pharmaceuticals, Inc. has a consensus price target of $668.57, signalling upside risk potential of 22.25%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,209.21 which suggests that it could grow by 29.25%. Given that Eli Lilly & Co. has higher upside potential than Madrigal Pharmaceuticals, Inc., analysts believe Eli Lilly & Co. is more attractive than Madrigal Pharmaceuticals, Inc..

Madrigal Pharmaceuticals, Inc. has a beta of -0.995, which suggesting that the stock is 199.535% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.506, suggesting its less volatile than the S&P 500 by 49.45%.

Madrigal Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.68% to investors and pays a quarterly dividend of $1.73 per share. Madrigal Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Madrigal Pharmaceuticals, Inc. quarterly revenues are $321.1M, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Madrigal Pharmaceuticals, Inc.'s net income of -$58.6M is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Madrigal Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 40.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals, Inc. is 13.20x versus 12.82x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -18.24% compared to Madrigal Pharmaceuticals, Inc.'s net margin of -9.34%. Madrigal Pharmaceuticals, Inc.'s return on equity of -42.53% beat Pfizer Inc.'s return on equity of 8.69%.

Madrigal Pharmaceuticals, Inc. has a consensus price target of $668.57, signalling upside risk potential of 22.25%. On the other hand Pfizer Inc. has an analysts' consensus of $28.58 which suggests that it could grow by 0.92%. Given that Madrigal Pharmaceuticals, Inc. has higher upside potential than Pfizer Inc., analysts believe Madrigal Pharmaceuticals, Inc. is more attractive than Pfizer Inc..

Madrigal Pharmaceuticals, Inc. has a beta of -0.995, which suggesting that the stock is 199.535% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.433, suggesting its less volatile than the S&P 500 by 56.687%.

Madrigal Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.12% to investors and pays a quarterly dividend of $0.43 per share. Madrigal Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 126.85% of its earnings as a dividend.

Madrigal Pharmaceuticals, Inc. quarterly revenues are $321.1M, which are smaller than Pfizer Inc. quarterly revenues of $17.6B. Madrigal Pharmaceuticals, Inc.'s net income of -$58.6M is higher than Pfizer Inc.'s net income of -$1.6B. Notably, Madrigal Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Pfizer Inc.'s PE ratio is 20.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals, Inc. is 13.20x versus 2.56x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

PTC Therapeutics, Inc. has a net margin of -18.24% compared to Madrigal Pharmaceuticals, Inc.'s net margin of -81.96%. Madrigal Pharmaceuticals, Inc.'s return on equity of -42.53% beat PTC Therapeutics, Inc.'s return on equity of --.

Madrigal Pharmaceuticals, Inc. has a consensus price target of $668.57, signalling upside risk potential of 22.25%. On the other hand PTC Therapeutics, Inc. has an analysts' consensus of $86.50 which suggests that it could grow by 27.64%. Given that PTC Therapeutics, Inc. has higher upside potential than Madrigal Pharmaceuticals, Inc., analysts believe PTC Therapeutics, Inc. is more attractive than Madrigal Pharmaceuticals, Inc..

Madrigal Pharmaceuticals, Inc. has a beta of -0.995, which suggesting that the stock is 199.535% less volatile than S&P 500. In comparison PTC Therapeutics, Inc. has a beta of 0.555, suggesting its less volatile than the S&P 500 by 44.489%.

Madrigal Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PTC Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Madrigal Pharmaceuticals, Inc. pays -- of its earnings as a dividend. PTC Therapeutics, Inc. pays out -- of its earnings as a dividend.

Madrigal Pharmaceuticals, Inc. quarterly revenues are $321.1M, which are larger than PTC Therapeutics, Inc. quarterly revenues of $164.7M. Madrigal Pharmaceuticals, Inc.'s net income of -$58.6M is higher than PTC Therapeutics, Inc.'s net income of -$135M. Notably, Madrigal Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while PTC Therapeutics, Inc.'s PE ratio is 8.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals, Inc. is 13.20x versus 3.21x for PTC Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.